tm
Seeing Is Believing
tm
Seeing Is Believing
BCLI is currently covered by 1 analysts with an average price target of $7.02. This is a potential upside of $5.3 (308.14%) from yesterday's end of day stock price of $1.72.
Brainstorm Cell Therapeutics's activity chart (see below) currently has 10 price targets and 21 ratings on display. The stock rating distribution of BCLI is 33.33% BUY and 66.67% HOLD.
Analysts average stock forecasts to be materialized ratio is 60% with an average time for these price targets to be met of 508 days.
Highest price target for BCLI is $2, Lowest price target is $2, average price target is $7.02.
Most recent stock forecast was given by JASON MCCARTHY from MAXIM GROUP on 11-Jul-2024. First documented stock forecast 20-Jan-2015.
Currently out of the existing stock ratings of BCLI, 1 are a BUY (33.33%), 2 are a HOLD (66.67%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
$2
$0.23 (12.99%)
4 months 22 days ago
(11-Jul-2024)
1/5 (20%)
$1.6 (400.00%)
82
Hold
$12
2 years 6 months 8 days ago
(25-May-2022)
5/5 (100%)
$8.99 (298.67%)
934
What is BCLI (Brainstorm Cell Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on BCLI (Brainstorm Cell Therapeutics) with a proven track record?
Which analyst has the current lower performing score on BCLI (Brainstorm Cell Therapeutics) with a proven track record?
Which analyst has the most public recommendations on BCLI (Brainstorm Cell Therapeutics)?
Which analyst is the currently most bullish on BCLI (Brainstorm Cell Therapeutics)?
Which analyst is the currently most reserved on BCLI (Brainstorm Cell Therapeutics)?
